Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAL-263 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | CAL-263 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| CAL-263 | DRUG | CAL-263 10 mg or placebo once daily for 7 days |
| Placebo | DRUG | CAL-263 10 mg or placebo once daily for 7 days |
Inclusion Criteria: 1. Age \>18 and \<55 years 2. Has a history of seasonal allergic rhinitis for at least 2 years 3. Has sensitivity to grass pollen demonstrated by a positive response to skin prick testing 4. Has a positive Radio Allergen Sorbent Test (class 2 or greater) for grass pollen during ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
CAL-263 is an investigational small molecule being studied for the treatment of allergic rhinitis. It has been evaluated in a Phase 1 clinical trial involving subjects with allergic rhinitis who were exposed to allergen in an environmental chamber. The drug is not approved and remains in clinical development.
CAL-263 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company conducted a Phase 1 clinical trial of CAL-263 in subjects with allergic rhinitis.
CAL-263 is in Phase 1 clinical development. A Phase 1 trial of CAL-263 has been completed. The drug is investigational and has not been approved for any use.
CAL-263 has been studied in one completed Phase 1 clinical trial, identified as NCT01066611. This trial investigated the effects of CAL-263 in subjects with allergic rhinitis exposed to allergen in an environmental chamber. The study enrolled 48 participants and was conducted in Austria.
Yes, the Phase 1 clinical trial of CAL-263 was a randomized, double-blind, placebo-controlled study. The trial enrolled 48 participants aged 18 years and older with allergic rhinitis. The study was conducted in Austria and has been completed.